Delving into the Latest Updates on Technetium Tc-99M Sestamibi Kit with Synapse

Overview

Basic Info

Drug Type

Small molecule drug, Diagnostic radiopharmaceuticals

Synonyms

99m Tc-sestamibi, 99m-Tc sestamibi, 99mTc sestamibi

+ [22]

Target-

Action-

Mechanism-

Therapeutic Areas

Cardiovascular DiseasesEndocrinology and Metabolic DiseaseOther Diseases

Active Indication

Diagnostic agentsHeart DiseasesHyperparathyroidism+ [2]

Inactive Indication

Mucocutaneous Lymph Node Syndrome

Originator Organization

Lantheus Medical Imaging, Inc.

Active Organization

Lantheus Medical Imaging, Inc.PDRadiopharma, Inc.

Shanghai Atom Kexing Pharmaceutical Colltd

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

United States (21 Dec 1990),

CardiomyopathiesContrast agents

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC36H66N6O6Tc

InChIKeyZBTQTVSNLRPJHI-ZKPGHZHMSA-N

CAS Registry109581-73-9

This clinical trial tests how well molecular breast imaging (MBI) works to guide the collection of a breast biopsy in patients with a breast abnormality. Currently, a biopsy is often guided by either ultrasound or mammography in order to ensure that a sample of the correct part of the breast is taken. Sometimes a lesion or part of the lesion cannot be seen on ultrasound or mammography, and, therefore, a biopsy guided with ultrasound or mammography may not be always be accurate. Studies have shown that high resolution MBI may have potential to improve the detection of some breast tumors. This trial uses a new high-resolution MBI system that may help perform a biopsy using MBI.

Start Date26 Aug 2021

Sponsor / Collaborator

Mayo Clinic

NCT01899833

/ Unknown statusPhase 2

A Prospective, Open-label, Multicenter Study With Blinded Over-reading Characterizing the Efficacy and Safety of 99mTc-EC-DG in the Evaluation of Coronary Artery Disease (CAD)

This study will compare how well a new radiolabeled imaging agent ECDG compares to the current testing for coronary artery disease (radiolabeled Sestamibi) during a rest and stress cardiac test as documented from results of a coronary angiogram (if performed).

Start Date10 Jan 2021

Sponsor / Collaborator

Cell Point LLC

100 Clinical Results associated with Technetium Tc-99M Sestamibi Kit

Login to view more data

100 Translational Medicine associated with Technetium Tc-99M Sestamibi Kit

Login to view more data

100 Patents (Medical) associated with Technetium Tc-99M Sestamibi Kit

Login to view more data

2,933

Literatures (Medical) associated with Technetium Tc-99M Sestamibi Kit

13 Jan 2025·European Heart Journal - Imaging Methods and Practice

A comparison between 64-projection and 32-projection myocardial perfusion scintigraphy

Article

Author: Golshani, Samad ; Abedi, Seyed Mohammad ; Farsavian, Ali Asghar ; Taghavi, Morteza ; Mostafavinia, Ali ; Nezhadnaderi, Pedram ; Karimi, Hanie ; Ghadirzadeh, Erfan ; Khorrami Moghaddam, Alireza ; Moradi, Amir ; Hosseinimehr, Seyed Jalal ; Daryabari, Seyede Sepide ; Mardanshahi, Alireza

AbstractAimsWhile most clinical guidelines recommend using a 64-projection view technique, some protocols do not specify a preference between 32-projection and 64-projection methods for conducting myocardial perfusion scintigraphy (MPS), which shows the lack of consensus in this matter. Nevertheless, these guidelines and protocols have not provided us with compelling evidence to support why the 64-projection technique is usually chosen. Thus, we aimed to determine if there is a significant difference between them in the assessment of cardiac perfusion and functional indices.Methods and resultsSixty-nine patients were included in this pilot prospective, cross-sectional, cross-over, same patient control protocol study and underwent 32- and 64-projection MPS at both stress and rest phases after injecting 740–925 MBq of 99mTc-MIBI for every patient. Then, cardiac indices, including summed stress, rest, and difference scores, extent-stress and rest, left ventricular volumes and ejection-fraction, peak filling rate (PFR), and time to peak filling rate (TTPF) were recorded. Lin’s concordance correlation coefficient was used to assess the agreement between protocols, and a paired sample t-test was used to compare the means of variables where appropriate. Findings revealed no significant difference as well as excellent/good agreement between the two methods in either the stress or rest state, except for the TTPF and PFR.ConclusionThe findings suggest that lower-projection techniques could be adequate for routine clinical assessments without sacrificing diagnostic accuracy. However, the poor agreement for PFR and TTPF indicates that the 32-projection method may not reliably assess diastolic function, implying that the 64-projection protocol is preferable when precise evaluations are necessary.

02 Jan 2025·Cureus

Facial Edema After Nuclear Stress Test

Article

Author: Saurborn, Emily ; Roth, Danielle ; Cook, Shane

Angioedema involves fluid accumulation into the interstitial spaces of the dermis, subcutaneous tissue, and mucosal surfaces. While usually benign and self-limited, angioedema can lead to laryngeal edema, a life-threatening condition. The most common causes are histamine-mediated allergic reactions. However, angioedema can also be mediated by bradykinin. Bradykinin-mediated angioedema can occur in the setting of hereditary deficiency of C1q esterase and after exposure to several medications. Drug-induced angioedema is most commonly a secondary complication of non-steroidal anti-inflammatory drug (NSAID) or sulfa drug use. All providers must be aware of the potential side effects of the medications they use or prescribe. We present a case of angioedema resulting from the use of technetium-99m sestamibi tracer injection during an adenosine nuclear stress test.

01 Jan 2025·Indian Journal of Urology

Reply to Letter for the Article, the Impact of Sestamibi Scan on Clinical Decision-Making for Renal Masses: An Observational Single-center Study. Yong, Courtney; Tong, Yan; Tann, Mark; Sundaram, Chandru P. Indian Journal of Urology. 40(3):151–155, Jul–Sep 2024

Article

Author: Tong, Yan ; Tann, Mark ; Yong, Courtney ; Sundaram, Chandru

100 Deals associated with Technetium Tc-99M Sestamibi Kit

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	Technetium Tc-99M Sestamibi Kit	V09GA01	DB09161

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Diagnostic agents	Japan	PDRadiopharma, Inc.	02 Apr 1993
Hyperparathyroidism	Japan	PDRadiopharma, Inc.	02 Apr 1993
Cardiomyopathies	United States	Lantheus Medical Imaging, Inc.	21 Dec 1990
Contrast agents	United States	Lantheus Medical Imaging, Inc.	21 Dec 1990
Heart Diseases	China	Shanghai Atom Kexing Pharmaceutical Colltd	-

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Mucocutaneous Lymph Node Syndrome	Preclinical	Taiwan Province	Lantheus Medical Imaging, Inc.	01 Aug 2005
Mucocutaneous Lymph Node Syndrome	Preclinical	Thailand	Lantheus Medical Imaging, Inc.	01 Aug 2005
Mucocutaneous Lymph Node Syndrome	Preclinical	South Korea	Lantheus Medical Imaging, Inc.	01 Aug 2005
Mucocutaneous Lymph Node Syndrome	Preclinical	Canada	Lantheus Medical Imaging, Inc.	01 Aug 2005
Mucocutaneous Lymph Node Syndrome	Preclinical	Philippines	Lantheus Medical Imaging, Inc.	01 Aug 2005
Mucocutaneous Lymph Node Syndrome	Preclinical	Brazil	Lantheus Medical Imaging, Inc.	01 Aug 2005
Mucocutaneous Lymph Node Syndrome	Preclinical	United States	Lantheus Medical Imaging, Inc.	01 Aug 2005

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


EANM2024	Not Applicable	Diabetes Mellitus	1	99mTc-MIBI (Dellon Tarsal Tunnel Decompression)	ppbdrdkdyk(awzdzsqswa) = sgxmyumzyb jbazfmwncy (cysgxgroyt ) View more	Positive	27 Sep 2024
EANM2024	Not Applicable	Chronic heart failure	-	Tc-MIBI (Non-ischemic CHF patients)	hvcyzczyzn(icbfgzcxfa) = lmxiavwxke pbfqnxkqnh (jaxfooohkm, 8.49 - 13.8)	-	27 Sep 2024
				Tc-MIBI (Control group)	hvcyzczyzn(icbfgzcxfa) = cbhbknneod pbfqnxkqnh (jaxfooohkm, 0.9 - 9.8)
EANM2024	Not Applicable	-	82	[99mTc]-sestamibi and [99mTc]-pertechnetate scintigraphy SPECT/CT (Tc-99m)	tnfwxcwjpg(msjdkfpgjn) = nztdebbsix dkqubcmomj (miiygptvfr, 0.3 (0.6 - 2.1)) View more	Positive	27 Sep 2024
EANM2024	Not Applicable	Vascular Diseases	40	99mTc-MIBI (Diabetic Patients)	(oecvhguszk) = mfepbhwpeo jwjfzlbedy (jpitgmhszj, 40.8)	-	27 Sep 2024
				99mTc-MIBI (Non-Diabetic Controls)	(oecvhguszk) = ioqtnkikxb jwjfzlbedy (jpitgmhszj, 33.4)
AUA2024	Not Applicable	Oncocytoma, Renal \| Renal Cell Carcinoma	-	99MTC-SESTAMIBI (Qualitative interpretation)	esrwsumtgd(atxluxsfrk) = jvwisdauak ihjmjzbtfh (xlllebzcbi ) View more	-	01 May 2024
				99MTC-SESTAMIBI (Quantitative interpretation using TBR cutoff of 0.46)	esrwsumtgd(atxluxsfrk) = eviuucghip ihjmjzbtfh (xlllebzcbi ) View more
SNMMI2023	Not Applicable	-	-	Tc-99m Sestamibi (Rest Study)	jxargcugke(aiucvpvvda) = hzibueueet wazsaynjpw (gfvqugeugl, 12.6)	-	28 Aug 2023
SNMMI2023	Not Applicable	Coronary Artery Disease	-	99mTc-sestamibi (Dynamic CZT-SPECT)	utlmjxxcuw(pmmrwxfiqu) = eqnjehfatu eaorfpxiep (ahnxlckcrh ) View more	-	28 Aug 2023
				99mTc-sestamibi (Conventional Gated SPECT MPI)	utlmjxxcuw(pmmrwxfiqu) = orxcnvsjff eaorfpxiep (ahnxlckcrh ) View more
SNMMI2023	Not Applicable	Diabetes Mellitus \| Myocardial Ischemia	-	99mTc-MIBI (Patients with diabetes (DB+))	nnzphkfniz(wknjwomanc): HR = 1.044 (95% CI, 1.004 - 1.018), P-Value = 0.003 View more	-	28 Aug 2023
				99mTc-MIBI (Patients without diabetes (DB-))
EANM2022	Not Applicable	Diabetes Mellitus, Type 2	-	99m Tc-sestamibi (Diabetics)	edirvctnrt(foncjmharc) = ifacfpoqfv qmhvacmdnp (otczpenijp, 23.2 - 26.2) View more	Positive	22 Sep 2022
				99m Tc-sestamibi (Non-Diabetics)	edirvctnrt(foncjmharc) = nvdiuejrql qmhvacmdnp (otczpenijp, 27.4 - 29.5) View more
EANM2022	Not Applicable	Neoadjuvant	64	99m Tc-sestamibi (Absolute 99m Tc tumor activity uptake quantification with Molecular Breast Imaging)	yfkqxjfmot(begabbecps) = ckbcunqtwa bmarpaoqup (pqqhnubibj, 32.2)	-	22 Sep 2022